MXCT — MAXCYTE, INC.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1287098 ·
Last close
$1.17
Market Cap
$120.75M
52W High
$1.87
52W Low
$0.64
ADV30
464,380
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 7,271,000 | 5,596,000 | -10,232,000 | -8,874,000 | 184,672,000 | 15,042,000 | 25,920,000 |
| Mar 2026 | 9,651,000 | 8,082,000 | -6,185,000 | -4,750,000 | 194,473,000 | 14,557,000 | 26,587,000 |
| Dec 2025 | 7,300,000 | 5,690,000 | -7,672,000 | -9,596,000 | 202,507,000 | 20,065,000 | 31,017,000 |
| Sep 2025 | 6,829,000 | 5,233,000 | -11,091,000 | -12,416,000 | 213,476,000 | 12,973,000 | 33,201,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,168,000
Investing CF
$19,062,000
Financing CF
$278,000
CapEx
$-1,337,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-266,233,000
Inventory
$7,631,000
Receivables
$4,246,000
ST Investments
$92,297,000
EBIT TTM
$-39,175,000
Pretax Income TTM
$-39,119,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,051,000
EBITDA
$-30,288,000
Free Cash Flow
$-13,138,125
Enterprise Value
$31,280,198
Total Cash
$105,690,000
Total Debt
$17,251,000
Shares Out
103,206,206
Trailing EPS
$-0.34
Book Value
$1.50
ROE
-20.4%
ROA
-10.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 33,026,000 | -45,285,000 | -44,630,000 | 202,507,000 | 31,017,000 | 171,490,000 | -34,410,000 |
| Dec 2024 | 38,627,000 | -51,197,000 | -41,055,000 | 239,470,000 | 33,219,000 | 206,251,000 | -27,610,000 |
| Dec 2023 | 41,288,000 | -48,299,000 | -37,923,000 | 268,274,000 | 36,107,000 | 232,167,000 | -21,686,000 |
| Dec 2022 | 44,261,000 | -27,361,000 | -23,571,000 | 286,653,000 | 32,685,000 | 253,968,000 | -14,783,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.25
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.17 · call volume: 50 · put volume: 1
Expected Move to 2026-10-16:
±$0.65
(55.56%) —
implied range
$0.52 –
$1.82
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMDX | Insight Molecular Diagnostics Inc. | $128.28M | $3.92 | — |
| ICCC | IMMUCELL CORP /DE/ | $90.19M | $9.93 | — |
| IBAC | IB Acquisition Corp. | $56.59M | $11.30 | — |
| NNNN | Anbio Biotechnology | $276.51M | $6.30 | — |
| ONMD | OneMedNet Corp | $38.54M | $0.65 | — |
News headlines (Yahoo Finance, 1h cache)
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
2026-09-23 12:05 · Yahoo
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
2026-08-19 23:01 · Yahoo
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
2026-08-19 12:05 · Yahoo
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
2026-08-13 05:03 · Yahoo
MaxCyte Q2 Earnings Call Highlights
2026-08-13 01:04 · Yahoo
MaxCyte Reports Second Quarter 2026 Financial Results
2026-08-12 20:05 · Yahoo
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
2026-07-21 12:05 · Yahoo
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
2026-07-15 20:05 · Yahoo
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors
2026-05-13 09:27 · Yahoo
MaxCyte, Inc. Q2 2026 Earnings Call Summary
2026-08-13 01:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.